AstraZeneca and Cellectis to collaborate for cell therapy and genomic medicine development
November 1, 2023Research and Development AstraZeneca, CGT, Pharmacy, cell therapy, cellectis, genomic medicine
AstraZeneca has announced a collaboration and investment agreement with Cellectis for the development of next generation cell and gene therapeutics …
Allyx Therapeutics shares phase 1a trial data for Alzheimer’s treatment
October 31, 2023Medical Communications Allyx Therpeutics, Alzheimer's disease, Neurology, clinical trial
Allyx Therapeutics has announced phase 1a single ascending dose study results at the 16th Clinical Trials on Alzheimer’s Disease (CTAD) …
NMPA approves CStone’s Cejemly for lymphoma treatment
October 31, 2023Medical Communications CStone, Cejemly, NMPA, Oncology, lymphoma
CStone Pharmaceuticals has announced that the National Medical Products Administration (NMPA) of China has approved its anti-PD-L1 antibody Cejemly (sugemalimab) …
First patient enrolled in Boan Biotech’s phase 3 trial for Nivolumab in China
October 30, 2023Research and Development Boan Biotech, China, Oncology, clinical trial, nivolumab
Boan Biotech has announced that the first patient has been enrolled in its phase 3 trial of its Nivolumab injection …
GSK shares results from phase 3 RUBY trial of Jemperli for endometrial cancer treatment
October 30, 2023Medical Communications Cancer, GSK, Jemperli, Oncology, endometrial cancer
GSK has announced positive headline results from an analysis of part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial which assessed …
Roche’s Vabysmo approved by FDA for retinal vein occlusion treatment
October 27, 2023Medical Communications FDA, Opthalmology, Roche, Vabysmo, retinal vein occlusion
Roche has announced that the US Food and Drug Administration (FDA) has approved Vabysmo (farcimab) for the treatment of macular …
Eli Lilly’s Omvoh receives FDA approval for ulcerative colitis treatment
October 27, 2023Medical Communications Eli Lilly, FDA, Gastrointestinal tract, Omvoh, ulcerative colitis
Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Omvoh (mirikizumab-mrkz) infusion (300mg/15mL)/injection (100mg/mL) for …
China’s NMPA approves ViiV Healthcare’s Vocabria in combination with Rekambys for HIV treatment
October 26, 2023Research and Development HIV, HIV/AIDS, NMPA, ViiV Healthcare, Vocabria
ViiV Healthcare has announced that the National Medical Products Administration (NMPA) of China has approved Vocabria (cabotegravir injection) used in …
Eisai shares new data for Leqembi for Alzheimer’s treatment
October 26, 2023Research and Development Alzheimer's, Biogen, Eisai, Neurology, lecanemab
Eisai and Biogen have announced that Eisai has shared new data for Leqembi (lecanemab-irmb) 100mg/mL injection for intravenous (IV) use …
FDA approves Servier Pharmaceuticals’ new MDS therapy
October 25, 2023Medical Communications FDA, Oncology, Servier Pharmaceuticals, myelodysplastic syndromes
The US Food and Drug Administration (FDA) has announced that it has approved Servier Pharmaceuticals’ Tibsovo (ivosidenib) for the treatment …
GSK shares new data for RSV vaccine Arexvy
October 25, 2023Research and Development Arexvy, GSK, Immunology, RSV, Vaccine
GSK announced positive results from its phase 3 trial which assessed the immune response and safety of Arexvy, its respiratory …
AstraZeneca’s sBLA for FluMist Quadrivalent accepted by FDA
October 24, 2023Medical Communications AstraZeneca, FDA, FluMist, Immunology, flu vaccine, sBLA
AstraZeneca has announced that the US Food and Drug Administration (FDA) has accepted for review its Supplemental Biologics License Agreement …
Samsung Biologics and Kurma Partners announce collaboration for development and manufacturing of biologics
October 24, 2023Business Services Kurma Partners, Pharmacy, Samsung BioLogics
Samsung Biologics and Kurma Partners have announced a strategic partnership for the development and manufacturing of biologics for Kurma Partners’ …
Roche announces acquisition of Telavant
October 23, 2023Business Services Gastrointestinal tract, Roche, Telavant
Roche has announced that it has entered into a definitive agreement to acquire Telavant Holdings, a Roivant company, owned by …
AstraZeneca and Daiichi Sankyo’s Enhertu approved in EU for treatment of HER2-mutant NSCLC
October 23, 2023Research and Development AstraZeneca, Daiichi Sankyo, Enhertu, NSCLC, Oncology
AstraZeneca and Daiichi Sankyo have announced that Enhertu (trastuzumab deruxtecan) has been approved in the EU as a monotherapy for …
Genentech shares data from phase 3 trials of Vabysmo for retinal vein occlusion treatment
October 10, 2023Research and Development Genentech, Opthalmology, Vabysmo, phase 3 trial, retinal vein occlusion
Genentech has announced positive topline long-term results from its global phase 3 BALATON and COMINO trials which assessed extended treatment …
First patient dosed in Transgene and BioInvent’s phase 1 trial
October 10, 2023Research and Development BioInvent, Oncology, Transgene, oncology, phase 1 trial
Transgene and BioInvent have announced that the first patient has been treated in the phase 1 part B clinical trial …
BMS acquires Mirati Therapeutics for $4.8bn
October 9, 2023Business Services BMS, Mirati Therapeutics, Oncology, acquisition, bristol myers squibb, oncology
Bristol Myers Squibb (BMS) and Mirati Therapeutics have announced that they have entered into a definitive agreement under which BMS …
GSK and Zhifei partner for shingles vaccine promotion in China
October 9, 2023Medical Communications GSK, Immunology, Shingrix, Vaccine, Zhifei, shingles
GSK has announced that it has come to an exclusive agreement with Chingqing Zhifei Biological Products to co-promote GSK’s shingles …
Sanofi shares new data for long-term efficacy of Nexviazyme for Pompe disease treatment
October 6, 2023Research and Development Nexviazyme, Pharmacy, Pompe disease, Sanofi
Sanofi has shared new data for the long-term efficacy of Nexviazyme (avalglucosidease alfa) for the treatment of Pompe disease at …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
